5279-23-2

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine is used as a potential therapeutic agent for psychiatric conditions such as schizophrenia and bipolar disorder, due to its antipsychotic and anxiolytic properties.
Used in Neurological Applications:
CSP is used as a potential neuroprotective agent, which may help in the treatment and prevention of neurodegenerative diseases and conditions.
Used in Anti-inflammatory Applications:
1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine is used as an anti-inflammatory agent, which may be beneficial in treating various inflammatory conditions and diseases.
Used in Research and Development:
CSP is used as a compound of interest in preclinical studies, where its unique chemical structure and diverse biological activities make it a promising candidate for further research and potential therapeutic development.

InChI:InChI=1/C17H19ClN2O3S/c1-23-17-5-3-2-4-16(17)19-10-12-20(13-11-19)24(21,22)15-8-6-14(18)7-9-15/h2-9H,10-13H2,1H3

Upstream product

• 14002-33-6 bis-(3-hydroxypropyl)amine 
• 100-39-0 benzyl bromide 
• 100-46-9 benzylamine 
• 627-30-5 1-chloro-3-hydroxypropane 
• 793-19-1 bis(2-methoxycarbonylethyl)benzylamine 
• 6938-07-4 N,N-bis(2-ethoxycarbonylethyl)benzylamine 

Downstream Products

• 34753-62-3 N-Benzylbis(3-chloropropyl)amine 
• 14002-33-6 bis-(3-hydroxypropyl)amine 
• 129917-35-7 Benzylbis<3-(2,3-dihydroxyphenoxy)propyl>amin-hydrochlorid 
• 129917-34-6 Benzylbis<3-(2,2-dimethyl-1,3-benzodioxol-4-yloxy)propyl>amin 
• 161693-95-4 8-benzyl-1,4,12-tritosyl-1,4,8,12-tetraazacyclopentadecane 
• 161693-97-6 8-benzyl-1,4,12-tri-Boc-1,4,8,12-tetraazacyclopentadecane 
• 161693-96-5 8-benzyl-1,4,8,12-tetraazacyclopentadecane 
• 180966-10-3 1,3,5-tris[(13-tert-butoxycarbonyl-1,9-dithia-5,13-diazacyclohexadec-5-yl)carbonylmethoxy]benzene 
• 180966-06-7 1-(13-Benzyl-1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-2-{3,5-bis-[2-(13-benzyl-1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-2-oxo-ethoxy]-phenoxy}-ethanone 
• 180966-19-2 1,3,5-tris[(13-tert-butoxycarbonyl-1,9-dithia-5,13-diazacyclohexadec-5-yl)carbonyl]benzene 
• 180966-16-9 (13-Benzyl-1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-[3,5-bis-(13-benzyl-1,9-dithia-5,13-diaza-cyclohexadecane-5-carbonyl)-phenyl]-methanone 

Relevant academic research and scientific papers

N-HETEROCYCLIC CARBENE (NHC) BASED LIGANDS AND RELATED METHODS

Polydentate macrocyclic NHCs (NHC ligands) and related methods are disclosed. Such ligands advantageously facilitate a variety of ligand coordination modes and stabilize oxidation states of metal complexes with a number of coordination environments and shapes. The NHC ligands described herein comprise pendant groups configured to facilitate a variety of reactions including: cis-trans isomerization, proton shuttling and facilitating changes in coordination environments as a result of redox reactions.

Synthesis and structural characterization of 20-membered macrocyclic rings bearing: Trans -chelating bis(N-heterocyclic carbene) ligands and the catalytic activity of their palladium(ii) complexes

Macrocycles consisting of a 20-membered ring containing two imidazolium salt functionalities and of the formula [PhCH2N(CH2CH2CH2)Im(CH2CH2CH2)2][Br]2 (Im = imidazole = 3a, benzimidazole = 3b) were synthesized in 70-75% yields. These salts serve as precursors to macrocycles containing two N-heterocyclic carbene (NHC) moieties. Reaction of the macrocyclic salts 3a and 3b with silver oxide afforded macrocyclic-bis(NHC)silver(i) complexes 4a and 4b. Single-crystal X-ray diffraction studies of macrocyclic-bis(NHC)silver(i) complex 4a revealed a tetranuclear silver core with a short Ag-Ag distance (2.9328 ?). Complexes 4a and 4b serve as carbene transfer reagents to Pd. The treatment of macrocyclic-bis(NHC)silver(i) complexes 4a and 4b with one equivalent of PdCl2(MeCN)2 in methylene chloride afforded square-planar trans-macrocyclic-bis(NHC)Pd(ii)X2 complexes 5a and 5b. Preliminary screening of these palladium complexes showed they are competent precatalysts for Heck and Suzuki coupling reactions.

TRIAZACYCLODODECANSULFONAMIDE ("TCD")-BASED PROTEIN SECRETION INHIBITORS

Provided herein are triazacyclododecansulfonamide ("TCD")-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY

The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

New bidentate trans-chelating N-heterocyclic carbene ligands for palladium

A family of imidazolium salts of the type [BnN(CH2CH 2CH2RIm)2]A·2[Cl] (Bn = CH2Ph; RIm = 1-methylimidazole (1a), 1-tert-butylimidazole (1b), 1-benzylimidazole (1c), 1-methylbenzimidazole (1d)), which contain a tertiary amine linking two imidazolium groups, has been synthesized. These imidazolium salts can be deprotonated with Ag2O to generate the Ag carbene complexes [{BnN(CH2CH2CH2 RIm)2}Ag].[AgCl2] (RIm = 1-methylimidazole (2a), 1-tert-butylimidazole (2b), 1-benzylimidazole (2c), 1-methylbenzimidazole (2d)). In the solid state 2d exists as an unusual tetramer, which consists of an [Ag2Cl4]2- core bridging two Ag(NHC) cations. Subsequent reaction of the Ag complexes with PdCl2(MeCN)2 generates Pd species of the type {BnN(CH 2CH2CH2RIm)2}PdCl 2 (RIm = 1-methylimidazole (3a), 1-tert-butylimidazole (3b), 1-benzylimidazole (3c), 1-methylbenzimidazole (3d)), which is a rare example of a family of Pd complexes that contain a bidentate trans-chelating N-heterocyclic carbene ligand. Compounds 3a and 3c were crystallographically characterized by X-ray crystallography and contain unusual 12-membered metallacycles. DFT calculations suggest that the preference for trans binding of the ligand is related to conformational effects of the linker. Compound 3b reacts with excess MeI to form {BnN(CH2CH2CH 2tBuIm)2}PdI2 (5b), a reaction in which we believe a Pd(IV) intermediate is generated. Compound 5b was crystallographically characterized. Compounds 3a-d are all active catalysts for the Heck reaction, and 3a can also catalyze the Suzuki reaction.

New linked macrocyclic systems derived from selectively protected S2N2 macrocycles

Novel application of a protecting group strategy has enabled a simple and efficient synthesis of the new tri-linked S2N2 macrocycles 12, 15, 17 and 20. This strategy involves the introduction of complementary protecting groups (R1 and R2) into the precursor macrocycle 4, which can then be manipulated to provide a synthetically versatile set of mono-N-protected S2N2 macrocyclic building blocks 5, 7 and 8.

First unequivocal synthesis of 1 or 8-N-monosubstituted 1,4,8,12-tetraazacyclopentadecane

A novel method derived from Kaden's modification of the Richman and Atkins's cyclization using tosylated synthons allows the unequivocal synthesis of 1 and 8-monofunctionalized 1,4,8,12-tetraazacyclo-pentadecane. Both syntheses are described.

Metal Chelates of Medical Interest, III. - 99mTc Complexes with Tetradentate Dicatechol Ligands

The dicatechol ligand bisamine hydrochloride, DIPACE (6), reduces the 99m- ion to lower valent 99mTc and subsequently forms a complex with the reduced 99mTc.The structure of benzylbisamine (4) is determined by X-ray crystallography.